Nothing Special   »   [go: up one dir, main page]

MX2022015772A - Proteínas enpp1 o enpp3 solubles y sus usos. - Google Patents

Proteínas enpp1 o enpp3 solubles y sus usos.

Info

Publication number
MX2022015772A
MX2022015772A MX2022015772A MX2022015772A MX2022015772A MX 2022015772 A MX2022015772 A MX 2022015772A MX 2022015772 A MX2022015772 A MX 2022015772A MX 2022015772 A MX2022015772 A MX 2022015772A MX 2022015772 A MX2022015772 A MX 2022015772A
Authority
MX
Mexico
Prior art keywords
enpp3
enpp1
proteins
deficiency
compositions
Prior art date
Application number
MX2022015772A
Other languages
English (en)
Inventor
Zhiliang Cheng
Demetrios Braddock
Steven Jungles
Paul Stabach
Original Assignee
Inozyme Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inozyme Pharma Inc filed Critical Inozyme Pharma Inc
Publication of MX2022015772A publication Critical patent/MX2022015772A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En determinados aspectos, la presente invención proporciona polipéptidos ENPP1 o ENPP3 solubles novedosos, así como composiciones y métodos para usar esas variantes para tratar una indicación 5 asociada a una deficiencia de ENPP1 o ENPP3. Las composiciones y métodos proporcionados en la presente descripción son útiles para tratar enfermedades asociadas con una deficiencia de ENPP1 o ENPP3 tales como calcificación patológica u osificación patológica.
MX2022015772A 2020-06-09 2021-06-08 Proteínas enpp1 o enpp3 solubles y sus usos. MX2022015772A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063036833P 2020-06-09 2020-06-09
PCT/US2021/036494 WO2021252549A1 (en) 2020-06-09 2021-06-08 Soluble enpp1 or enpp3 proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2022015772A true MX2022015772A (es) 2023-05-19

Family

ID=76731053

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015772A MX2022015772A (es) 2020-06-09 2021-06-08 Proteínas enpp1 o enpp3 solubles y sus usos.

Country Status (14)

Country Link
US (1) US20230313158A1 (es)
EP (1) EP4162036A1 (es)
JP (1) JP2023529892A (es)
KR (1) KR20230042263A (es)
CN (1) CN116157145A (es)
AR (1) AR122578A1 (es)
AU (1) AU2021286502A1 (es)
BR (1) BR112022024958A2 (es)
CA (1) CA3181983A1 (es)
CO (1) CO2023000016A2 (es)
IL (1) IL298853A (es)
MX (1) MX2022015772A (es)
TW (1) TW202214849A (es)
WO (1) WO2021252549A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022450370A1 (en) * 2022-03-30 2024-10-24 Yale University Method and compositions for treatment, amelioration, and/or prevention of diffuse idiopathic skeletal hyperostosis (dish)

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
WO1993018755A1 (en) 1992-03-25 1993-09-30 Depomed Systems, Incorporated Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
PT998271E (pt) 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
EP1002119A1 (en) 1997-07-31 2000-05-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeted hsv vectors
EP1242057A2 (en) 1999-11-02 2002-09-25 DepoMed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
AU767812B2 (en) 2000-02-04 2003-11-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
US20030031711A1 (en) 2001-05-29 2003-02-13 Fara John W. Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
EP1438027A1 (en) 2001-10-25 2004-07-21 DepoMed, Inc. Methods of treatment using a gastric retained losartan dosage
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20070207124A1 (en) 2004-10-28 2007-09-06 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
DK2097533T3 (da) 2006-11-28 2010-11-01 Proyecto Biomedicina Cima Sl Viral vektor og anvendelser deraf
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
SG193024A1 (en) 2011-03-11 2013-10-30 Synageva Biopharma Corp Npp1 fusion proteins
WO2014126965A2 (en) 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
GB2526339A (en) 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
EP3194430A1 (en) 2014-09-16 2017-07-26 Universitat Autònoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
ES2981606T3 (es) * 2014-12-19 2024-10-09 Inozyme Pharma Inc NPP1 soluble para su uso en un método para el tratamiento del pseudoxantoma elástico
CA2984947A1 (en) 2015-05-19 2016-11-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
US11364284B2 (en) * 2016-06-16 2022-06-21 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
AU2017306549A1 (en) 2016-08-05 2019-02-21 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
US12134790B2 (en) * 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
JP2021523139A (ja) * 2018-05-08 2021-09-02 イエール ユニバーシティ 腎石症の進行を遅らせるための組成物および方法
EP3844280A4 (en) 2018-08-31 2022-09-14 Yale University ENPP1 POLYPEPTIDES AND METHODS OF USE
BR112021020037A2 (pt) 2019-04-05 2021-12-07 Univ Yale Polipeptídeos enpp1 e métodos para o uso dos mesmos

Also Published As

Publication number Publication date
KR20230042263A (ko) 2023-03-28
IL298853A (en) 2023-02-01
AR122578A1 (es) 2022-09-21
CA3181983A1 (en) 2021-12-16
CO2023000016A2 (es) 2023-02-16
BR112022024958A2 (pt) 2022-12-27
JP2023529892A (ja) 2023-07-12
US20230313158A1 (en) 2023-10-05
EP4162036A1 (en) 2023-04-12
CN116157145A (zh) 2023-05-23
TW202214849A (zh) 2022-04-16
AU2021286502A1 (en) 2023-01-19
WO2021252549A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
DE602006012013D1 (de) Proteasom-hemmer und verwendungsverfahren dafür
WO2021007428A3 (en) Molecules, compositions and methods for treatment of cancer
MX2009009200A (es) Tratamiento de enfermedades caracterizadas por la inflamacion.
MA42471A (fr) Compositions comprenant des souches bactériennes
EA201900561A1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство
EA201990619A1 (ru) Fgf21 мутанты и их применение
MY193349A (en) Anti-vegf protein compositions and methods for producing the same
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
TW200745162A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MY149606A (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
SG165339A1 (en) Incorporation of non-naturally encoded amino acids into proteins
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2019003077A (es) Anticuerpos novedosos contra el factor xi y sus usos.
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
MX2022015772A (es) Proteínas enpp1 o enpp3 solubles y sus usos.
MX2021008503A (es) Tratamiento de enfermedades que involucran deficiencia de enpp1 o enpp3.
MX2024005649A (es) Proteinas quimericas basadas en sirp1a y cd40l.
MX2022014733A (es) Composiciones y métodos para inhibir la proliferación de células musculares lisas vasculares.
WO2021041324A3 (en) Compositions and methods for the treatment of pathological pain and itch
WO2020176461A3 (en) Methods and compositions for treating neuroendocrine prostate cancer
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie